One year’s treatment with the long-acting injectable paliperidone palmitate improved function and sleep quality in a sample of 90 adults with schizophrenia, reports Psych Congress.

The improvements began around the third month of treatment.

“Poorer function in schizophrenia is related to poorer quality of sleep and to an increased prevalence of sleep disturbances and insomnia of all types in schizophrenic patients,” wrote Adolfo Benito in a poster abstract. “Drugs such as long-acting injectable paliperidone palmitate have been shown to be effective in improving both function and sleep.”

To evaluate the evolution of sleep and function benefits associated with the long-acting injectable atypical antipsychotic, Benito tracked 97 adult patients from 3 mental health units in Toledo, Spain for 1 year, from when they began treatment with paliperidone palmitate. Seven participants dropped out during the study.